UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 28, 2003

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from        to       

Commission file number: 0-24663

ASPECT MEDICAL SYSTEMS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	04-2985553
(State or Other Jurisdiction of	(I.R.S. Employer Identification No.)
Incorporation or Organization)
141 Needham Street, Newton, Massachusetts	02464-1505
(Address of Principal Executive Offices)	(Zip Code)

(617) 559-7000
(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES x NO o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

YES x NO o

The Registrant had 19,420,184 shares of Common Stock, $0.01 par value per share, outstanding as of August 4, 2003.

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION
	Item 1. Financial Statements
		CONSOLIDATED BALANCE SHEETS
		CONSOLIDATED STATEMENTS OF OPERATIONS
		CONSOLIDATED STATEMENTS OF CASH FLOWS
		NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
	Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
	Item 3. Qualitative and Quantitative Disclosures About Market Risk
	Item 4. Controls and Procedures
PART II — OTHER INFORMATION
	Item 1. Legal Proceedings
	Item 2. Changes in Securities and Use of Proceeds
	Item 3. Defaults Upon Senior Securities
	Item 4. Submission of Matters to a Vote of Security Holders
	Item 5. Other Information
	Item 6. Exhibits and Reports on Form 8-K
SIGNATURE
EXHIBIT INDEX
EX-31.1 CERTIFICATION OF CEO
EX-31.2 CERTIFICATION OF CFO
EX-32.1 CERTIFICATION OF CEO
EX-32.2 CERTIFICATION OF CFO

ASPECT MEDICAL SYSTEMS, INC.

TABLE OF CONTENTS

		Page
PART I	FINANCIAL INFORMATION		1
Item 1.	Financial Statements (Unaudited)		1
	Consolidated Balance Sheets as of June 28, 2003 and December 31, 2002		1
	Consolidated Statements of Operations for the Three and Six Months Ended June 28, 2003 and June 29, 2002		2
	Consolidated Statements of Cash Flows for the Six Months Ended June 28, 2003 and June 29, 2002		3
	Notes to Consolidated Financial Statements		4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		31
Item 4.	Controls and Procedures		31
PART II	OTHER INFORMATION		32
Item 1.	Legal Proceedings		32
Item 2.	Changes in Securities and Use of Proceeds		32
Item 3.	Defaults Upon Senior Securities		32
Item 4.	Submission of Matters to a Vote of Security Holders		32
Item 5.	Other Information		32
Item 6.	Exhibits and Reports on Form 8-K		33
SIGNATURE			34

PART I — FINANCIAL INFORMATION

Item 1.      Financial Statements.

ASPECT MEDICAL SYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS

			June 28,			December 31,
			2003			2002
			(Unaudited)
ASSETS
Current assets:
	Cash and cash equivalents		$	13,045,400		$	11,542,833
	Restricted cash			5,100,000			5,100,000
	Marketable securities			13,900,247			20,222,500
	Accounts receivable, net of allowance of $295,000 at June 28, 2003 and $408,000 at December 31, 2002			5,720,671			4,666,098
	Current portion of investment in sales-type leases			1,836,747			1,859,237
	Inventory, net			1,738,325			2,333,385
	Other current assets			1,910,290			1,319,091
		Total current assets		43,251,680			47,043,144
Property and equipment, net				3,282,991			4,121,560
Long-term investment in sales-type leases				2,330,022			2,282,751
Long-term portion of notes receivable from related parties				751,375			1,032,572
		Total assets	$	49,616,068		$	54,480,027
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
	Current portion of long-term debt		$	825,356		$	887,538
	Accounts payable			1,300,940			1,246,567
	Accrued liabilities			6,938,787			7,127,091
	Deferred revenue			993,706			1,047,651
		Total current liabilities		10,058,789			10,308,847
Long-term portion of deferred revenue				5,939,392			6,359,210
Long-term debt				838,598			1,015,101
Commitments and contingencies
Stockholders’ equity:
	Preferred Stock, $.01 par value; 5,000,000 shares authorized, no shares issued or outstanding			—			—
	Common Stock, $.01 par value; 60,000,000 shares authorized, 19,419,871 and 19,370,823 shares issued and outstanding at June 28, 2003 and December 31, 2002, respectively			194,199			193,708
	Additional paid-in capital			130,762,645			130,606,576
	Notes receivable from employees and directors			(127,149	)		(271,049	)
	Accumulated other comprehensive income			21,733			20,900
	Accumulated deficit			(98,072,139	)		(93,753,266	)
		Total stockholders’ equity		32,779,289			36,796,869
		Total liabilities and stockholders’ equity	$	49,616,068		$	54,480,027

The accompanying notes are an integral part of these consolidated financial statements.

1

ASPECT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

			Three Months Ended						Six Months Ended
			June 28, 2003			June 29, 2002			June 28, 2003			June 29, 2002
			(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Revenue			$	10,708,844		$	10,051,223		$	20,836,134		$	19,737,789
Costs of revenue				2,716,429			3,024,051			5,265,889			6,541,587
Gross profit margin				7,992,415			7,027,172			15,570,245			13,196,202
Operating expenses:
	Research and development			1,863,797			2,026,131			3,744,753			3,962,675
	Sales and marketing			5,925,118			6,957,166			12,241,736			14,313,671
	General and administrative			2,182,600			1,933,915			4,281,388			3,783,979
		Total operating expenses		9,971,515			10,917,212			20,267,877			22,060,325
Loss from operations				(1,979,100	)		(3,890,040	)		(4,697,632	)		(8,864,123	)
Interest income				236,359			283,486			486,345			628,097
Interest expense				(52,456	)		(55,284	)		(107,586	)		(125,330	)
Net loss			$	(1,795,197	)	$	(3,661,838	)	$	(4,318,873	)	$	(8,361,356	)
Net loss per share:
	Basic and diluted		$	(0.09	)	$	(0.20	)	$	(0.22	)	$	(0.47	)
Weighted average shares used in computing net loss per share:
	Basic and diluted			19,394,827			17,863,241			19,387,987			17,839,814

The accompanying notes are an integral part of these consolidated financial statements.

2

ASPECT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

					Six Months Ended
					June 28,			June 29,
					2003			2002
					(Unaudited)			(Unaudited)
Cash flows from operating activities:
	Net loss				$	(4,318,873	)	$	(8,361,356	)
	Adjustments to reconcile net loss to net cash used for operating activities –
		Depreciation and amortization				1,098,666			1,268,140
		Provision for doubtful accounts				(100,000	)		—
		Compensation expense related to stock options				13,537			22,012
		Changes in assets and liabilities –
			(Increase) decrease in accounts receivable			(954,573	)		200,592
			Decrease in inventory			595,060			1,713,474
			Increase in other assets			(428,421	)		(419,481	)
			Increase in investment in sales-type leases			(24,781	)		(431,857	)
			Increase (decrease) in accounts payable			54,373			(687,887	)
			Decrease in accrued liabilities			(188,304	)		(566,783	)
			Decrease in deferred revenue			(473,763	)		(73,439	)
				Net cash used for operating activities		(4,727,079	)		(7,336,585	)
Cash flows from investing activities:
	Loans to related parties					—			(50,000	)
	Payments on loans to related parties					118,419			81,347
	Acquisition of property and equipment					(260,097	)		(605,825	)
	Purchases of marketable securities					(4,900,000	)		(3,295,195	)
	Proceeds from sales and maturities of marketable securities					11,223,086			16,996,495
				Net cash provided by investing activities		6,181,408			13,126,822
Cash flows from financing activities:
	Proceeds from sale of investment in sales-type leases					265,730			313,350
	Principal payments on debt related to investment in sales-type leases					(504,415	)		(496,076	)
	Proceeds from issuance of common stock					143,023			304,842
	Payments received on notes receivable from employees and directors					143,900			25,658
				Net cash provided by financing activities		48,238			147,774
Net increase in cash and cash equivalents						1,502,567			5,938,011
Cash and cash equivalents, beginning of period						11,542,833			14,325,348
Cash and cash equivalents, end of period					$	13,045,400		$	20,263,359
Supplemental disclosure of cash flow information:
	Interest paid				$	107,586		$	126,122

The accompanying notes are an integral part of these consolidated financial statements.

3

ASPECT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1)      Basis of Presentation

     The accompanying unaudited consolidated financial statements of Aspect Medical Systems, Inc. (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all normal, recurring adjustments considered necessary for a fair presentation have been included. The consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2002 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”). Interim results of operations are not necessarily indicative of the results to be expected for the full year or any other interim period.

(2)      Summary of Significant Accounting Policies

     A summary of the significant accounting policies used by the Company in the preparation of its financial statements follows:

Principles of Consolidation

     The consolidated financial statements include the accounts of the Company and all wholly-owned subsidiaries. All material intercompany accounts and transactions have been eliminated.

Foreign Currency Translation

     The functional currency of the Company’s international subsidiaries is the U.S. dollar; therefore, translation gains and losses from such entities are recorded in the consolidated statements of operations. Foreign currency transaction gains and losses have not been material.

Cash, Cash Equivalents and Marketable Securities

     The Company invests its excess cash in money market accounts, certificates of deposit, U.S. Treasury bills, high-grade commercial paper and debt obligations of various government agencies. The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

     The Company accounts for its investments in marketable securities in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 115, Accounting for Certain Investments in Debt and Equity Securities. In accordance with SFAS No. 115, the Company has classified all of its investments in marketable securities as available-for-sale at June 28, 2003 and December 31, 2002. The marketable securities are reported at fair value, with any unrealized gains and losses excluded from earnings and reported as a separate component of stockholders’ equity as other comprehensive income (loss).

Revenue Recognition

     The Company recognizes revenue from equipment sales, disposable product sales and sales-type leases at the time of product shipment when collectibility is reasonably assured. Payments received prior to shipment are recorded as deferred revenue. The Company has entered into certain licensing and distribution agreements for which payments received in advance are recorded as deferred revenue. Revenue under these agreements is recognized as earned per the terms of the respective agreements. The Company does not record a provision for estimated sales returns because historically the Company has experienced only minimal returns that were not covered by warranty reserves. All shipping and handling costs are included in cost of revenue.

4

ASPECT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

     In connection with the Stock Purchase Agreement with Boston Scientific Corporation (“BSC”) discussed in Note 9, the Company recorded approximately $6,300,000 of deferred revenue. The deferred revenue is being recognized ratably over the term of the OEM product development and distribution agreement with BSC. The term of this agreement continues until such time that BSC is no longer distributing the Company’s products, but in no event will extend beyond December 31, 2012.

Research and Development Costs

     The Company charges research and development costs to operations as incurred. Research and development costs include costs associated with new product development, product improvements and extensions, clinical studies and project consulting expenses.

Accounts Receivable

     Estimates are used in determining the Company’s allowance for doubtful accounts based on the Company’s historical collections experience, historical write-offs of its receivables, current trends, credit policy and a percentage of the Company’s accounts receivable by aging category. The Company also reviews the credit quality of its customer base as well as changes in the Company’s credit policies. The Company continually monitors collections and payments from its customers.

Inventory

     The Company values inventory at the lower of cost or estimated market, and determines cost on a first-in, first-out basis. The Company regularly reviews inventory quantities on hand and records a provision for excess or obsolete inventory primarily based on production history and on its estimated forecast of product demand. The medical industry in which the Company markets its products is characterized by rapid product development and technological advances that could result in obsolescence of inventory. Additionally, the Company’s estimates of future product demand may prove to be inaccurate, in which case it will need to change its estimate of the provision required for excess and obsolete inventory. If revisions are deemed necessary, the Company would recognize the adjustments in its costs of revenue at the time of the determination.

Investment in Sales-Type Leases

     The Company follows SFAS No. 13, Accounting For Leases, for its investment in sales-type leases. Under the Company’s sales-type leases, customers purchase BIS Sensors and the BIS monitor for the purchase price of the BIS Sensors plus an additional charge per BIS Sensor to pay for the purchase price of the BIS monitor and related financing costs over the term of the agreement. In accordance with SFAS No. 13, the minimum lease payment, consisting of the additional charge per BIS Sensor, less the unearned interest income, which is computed at the interest rate implicit in the lease, is recorded as net investment in sales-type leases. The cost of the BIS monitor acquired by the customer is recorded as costs of revenue in the same period.

     In addition, the Company periodically reviews and assesses the net realizability of its investment in sales-type leases. This review includes determining if a customer who entered into a sales-type lease is significantly underperforming relative to the customer’s committed level of BIS Sensor purchases. If this review results in a lower estimate of the net realizable investment balance, an allowance for the unrealized amount is established in the period in which the estimate is changed and is charged to revenue.

5

ASPECT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Warranty

     Equipment that the Company sells is generally covered by a warranty period of one year. The Company accrues a warranty reserve for estimated costs to provide warranty services. The Company’s estimate of costs to service its warranty obligations is based on historical experience and an expectation of future conditions. Warranty expense for the three and six months ended June 28, 2003, and accrued warranty cost, included in accrued liabilities in the consolidated balance sheet at June 28, 2003, was as follows:

	Three Months Ended						Six Months Ended
	June 28, 2003			June 29, 2002			June 28, 2003			June 29, 2002
Beginning balance	$	169,907		$	953,414		$	367,798		$	1,090,120
Warranty expense		8,222			259,848			(175,505	)		139,426
Deductions and other		(15,613	)		(71,467	)		(29,777	)		(87,751	)
Ending balance	$	162,516		$	1,141,795		$	162,516		$	1,141,795

Guarantees

     The Company guarantees operating lease obligations of its subsidiaries for the lease of office space and automobiles. The maximum potential future payment under these financial guarantees was approximately $224,000 at June 28, 2003.

Advertising Costs

     Advertising costs are expensed as incurred. These costs are included in sales and marketing expense in the consolidated statements of operations.

Property and Equipment

     Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related equipment. Equipment held under capital leases is stated at the lower of the fair market value of the equipment or the present value of the minimum lease payments at the inception of the lease and is amortized on a straight-line basis over the shorter of the lives of the related assets or the term of the leases. Repair and maintenance expenditures are charged to expense as incurred.

Income Taxes

     The Company accounts for income taxes in accordance with SFAS No. 109, Accounting for Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences, utilizing currently enacted tax rates, of temporary differences between the carrying amounts and the tax basis of assets and liabilities. Deferred tax assets are recognized, net of any valuation allowance, for the estimated future tax effects of deductible temporary differences and tax operating loss and credit carryforwards.

Concentration of Credit Risk and Single or Limited Source Suppliers

     Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents, accounts receivable, investment in sales-type lease receivables and marketable securities. To minimize the financial statement risk with respect to accounts receivable and investment in sales-type lease receivables, the Company maintains reserves for potential credit losses and such losses, in the aggregate, have not exceeded management’s expectations. The Company maintains cash, cash equivalents and investments in marketable securities with various financial institutions. The Company performs periodic evaluations of the relative credit quality of investments and Company policy is designed to limit exposure to any one institution or type of investment. The primary objective of the Company’s investment strategy is the safety of the principal invested. The Company does not maintain foreign exchange contracts or other off-balance sheet financial investments.

6

ASPECT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

     The Company currently obtains certain key components of its products from single or limited sources. The Company purchases components pursuant to purchase orders rather than long-term supply agreements and generally does not maintain large volumes of inventory. The Company has experienced shortages and delays in obtaining certain components of its products in the past. There can be no assurance that the Company will not experience similar shortages or delays in the future. The disruption or termination of the supply of components or a significant increase in the costs of these components from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.

Net Loss Per Share

     In accordance with SFAS No. 128, Earnings Per Share, basic and diluted net loss per share amounts for the three and six months ended June 28, 2003 and June 29, 2002, were computed by dividing the net loss available to common stockholders by the weighted average number of shares of common stock outstanding during those periods.

     All shares of restricted common stock, stock options and warrants have been excluded from the calculation of diluted net loss per share since the inclusion of such amounts would be antidilutive.

Comprehensive Income (Loss)

     Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other than the Company’s net loss, the only other element of comprehensive income (loss) impacting the Company is the unrealized gains (losses) on its marketable securities for all periods presented.

Stock-Based Compensation

     SFAS No. 123, Accounting for Stock-Based Compensation, requires the measurement of the fair value of stock options or warrants to be included in the statement of income or disclosed in the notes to financial statements. The Company accounts for stock-based compensation for employees under APB Opinion No. 25 and follows the disclosure-only alternative under SFAS No. 123. The Company has computed the weighted-average fair value of options granted in the three and six months ended June 28, 2003 and June 29, 2002 using the Black-Scholes option-pricing model pursuant to SFAS No. 123. The following table shows the weighted average assumptions used in the applicable periods and the weighted average fair market value of the options granted in each period.

	Three Months Ended						Six Months Ended
	June 28, 2003			June 29, 2002			June 28, 2003			June 29, 2002
Risk-free interest rate		3.75	%		4.40	%		3.98	%		4.40	%
Expected dividend yield		—			—			—			—
Expected life of options	5 years			5 years			5 years			5 years
Expected volatility		75	%		75	%		75	%		75	%
Weighted average fair market value of options granted	$	3.94		$	4.30		$	3.05		$	7.48

7

ASPECT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

     If the Company had recognized compensation cost for these awards consistent with SFAS No. 123, the Company’s net loss and pro forma net loss per common share would have been increased to the following pro forma amounts:

			Three Months Ended						Six Months Ended
			June 28, 2003			June 29, 2002			June 28, 2003			June 29, 2002
Net loss:
	Net loss as reported		$	(1,795,197	)	$	(3,661,838	)	$	(4,318,873	)	$	(8,361,356	)
		Add: Stock-based compensation expense included in reported net loss		—			9,188			13,537			22,012
		Deduct: Stock-based compensation expense determined under fair value based method for all awards		(1,924,197	)		(2,038,944	)		(3,787,784	)		(3,986,212	)
	Pro forma net loss		$	(3,719,394	)	$	(5,691,594	)	$	(8,093,120	)	$	(12,325,556	)
Net loss per share:
		Basic and diluted net loss per common share:
		As reported	$	(0.09	)	$	(0.20	)	$	(0.22	)	$	(0.47	)
		Pro forma	$	(0.19	)	$	(0.32	)	$	(0.42	)	$	(0.69	)

     The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions, including expected stock price volatility. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. Also, because stock options vest over several years and the Company expects to grant stock options in future years, the above pro forma results of applying the provisions of SFAS No. 123 are not necessarily representative of the pro forma results in future years.

Use of Estimates

     The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

     The estimated fair market values of the Company’s financial instruments, which include cash equivalents, marketable securities, accounts receivable, investment in sales-type leases, accounts payable and long-term debt, approximate their carrying values.

Reclassifications

     Certain amounts in the prior years’ financial statements have been reclassified to conform with the current-year presentation.

8

ASPECT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Recent Accounting Pronouncements

     In November 2002, the FASB issued Financial Interpretation No. 45, (“FIN 45”), Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others. FIN 45 requires a guarantor to disclose (a) the nature of the guarantee, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments under the guarantee; (c) the carrying amount of the liability, if any, for the guarantor’s obligations under the guarantee; and (d) the nature and extent of any recourse provisions or available collateral that would enable the guarantor to recover the amounts paid under the guarantee. FIN 45 also clarifies that a guarantor is required to recognize, at the inception of a guarantee, a liability at fair value for the obligations it has undertaken in issuing the guarantee, including its ongoing obligation to stand ready to perform over the term of the guarantee in the event that the specified triggering events or conditions occur. The initial recognition and initial measurement provisions of FIN 45 are applicable on a prospective basis to guarantees issued or modified after December 31, 2002. FIN 45 also addresses the disclosure requirements regarding product warranties. Instead of disclosing the maximum potential amount of future payments under the product warranty guarantee, a guarantor is required to disclose its accounting policy and methodology used in determining its liability for product warranties, as well as a tabular reconciliation of the changes in the guarantor’s product warranty liability for the reporting period. The Company adopted FIN 45 as of January 1, 2003. The adoption of FIN 45 did not have a material effect on the Company’s results of operations, cash flows or financial position.

     In January 2003, the FASB issued FIN 46, Consolidation of Variable Interest Entities. FIN 46 requires that if an entity has a controlling financial interest in a variable interest entity, the assets, liabilities and results of activities of the variable interest entity should be included in the consolidated financial statements of the entity. FIN 46 is effective immediately for all new variable interest entities created or acquired after January 31, 2003. For variable interest entities created or acquired prior to February 1, 2003, the provisions of FIN 46 must be applied for the first interim or annual period beginning after June 15, 2003. The Company adopted FIN 46 as of January 1, 2003. The adoption of FIN 46 did not have a material effect on the Company’s results of operations, cash flows or financial position.

(3)    Comprehensive Income (Loss)

     The Company’s total comprehensive income (loss) is as follows:

		Three Months Ended						Six Months Ended
		June 28, 2003			June 29, 2002			June 28, 2003			June 29, 2002
		(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Net loss		$	(1,795,197	)	$	(3,661,838	)	$	(4,318,873	)	$	(8,361,356	)
Other comprehensive income (loss):
	Unrealized (loss) gain on marketable securities		(9,827	)		17,932			833			(31,520	)
Comprehensive loss		$	(1,805,024	)	$	(3,643,906	)	$	(4,318,040	)	$	(8,392,876	)

(4)      Investment in Sales-Type Leases

     The components of the Company’s net investment in sales-type leases are as follows:

		June 28,		December 31,
		2003		2002
		(Unaudited)
Total minimum lease payments receivable		$	5,111,869	$	5,091,303
	Less — unearned interest		945,100		949,315
Net investment in sales-type leases			4,166,769		4,141,988
	Less — current portion		1,836,747		1,859,237
		$	2,330,022	$	2,282,751

9

ASPECT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(5)      Inventory

     Inventory consists of the following:

	June 28,		December 31,
	2003		2002
	(Unaudited)
Raw materials	$	808,884	$	1,060,709
Work-in-progress		131,797		129,673
Finished goods		797,644		1,143,003
	$	1,738,325	$	2,333,385

(6)      Segment Information and Enterprise Reporting

     The Company operates in one reportable segment as it markets and sells one family of anesthesia monitoring systems. The Company does not disaggregate financial information by product or geographically, other than export sales by region and sales by product, for management purposes. Substantially all of the Company’s assets are located within the United States. All of the Company’s products are manufactured in the United States.

     Revenue by geographic destination and as a percentage of total revenue is as follows:

		Three Months Ended				Six Months Ended
		June 28, 2003		June 29, 2002		June 28, 2003		June 29, 2002
		(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)
Geographic Area by Destination
	Domestic	$	8,678,204	$	8,520,710	$	16,618,538	$	16,370,433
	International		2,030,640		1,530,513		4,217,596		3,367,356
		$	10,708,844	$	10,051,223	$	20,836,134	$	19,737,789

		Three Months Ended						Six Months Ended
		June 28, 2003			June 29, 2002			June 28, 2003			June 29, 2002
		(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Geographic Area by Destination
	Domestic		81	%		85	%		80	%		83	%
	International		19			15			20			17
			100	%		100	%		100	%		100	%

     The Company did not have sales in any individual country, other than the United States, that accounted for more than 10% of the Company’s total revenue for the three and six months ended June 28, 2003 and June 29, 2002.

10

ASPECT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(7)      Related Party Transactions

     Through April 30, 2002, the Company loaned, on a full recourse basis, an aggregate of $1,441,000, to an officer, certain employees and a consultant of the Company. In May 2002, the Company loaned, on a full recourse basis, $50,000 to another officer of the Company, which together with accrued interest, was paid in full in March 2003, after that officer left the employ of the Company. All loans are evidenced by promissory notes bearing interest with rates ranging from 5.00% to 8.00% per annum. The loans are payable over periods ranging from one to five years and in each case are secured by assets of the borrower, including shares of the Company’s common stock owned by the borrower. The long-term portion of the loans is included in long-term notes receivable from related parties and the short-term portion of approximately $290,000 and $128,000 at June 28, 2003 and December 31, 2002, respectively, is included in other current assets in the accompanying consolidated balance sheets. The aggregate outstanding balance on these loans at June 28, 2003 and December 31, 2002 was approximately $1,042,000 and $1,160,000, respectively.

     In January 2002, the Company entered into a consulting agreement with one of its directors to provide consulting, advisory and neurodiagnostics business planning services to the Company. Effective April 11, 2003, this director resigned from the Company’s Board of Directors. As of June 28, 2003, the Company has paid approximately $9,000 to this former director under this consulting agreement.

(8)      Loan Agreements

     In May 2001, the Company entered into an agreement with a commercial bank for a revolving line of credit. The Company is entitled to borrow up to $5,000,000 under the revolving line of credit, which expires in May 2004 and, subject to annual review by the commercial bank, may be extended at the discretion of the commercial bank. Interest on any borrowings under the revolving line of credit is, at the election of the Company, either the prime rate or at LIBOR plus 2.25%. Up to $1,500,000 of the $5,000,000 revolving line of credit is available for standby letters of credit. At June 28, 2003, the Company had outstanding standby letters of credit totaling $190,137.

     The revolving line of credit agreement contains restrictive covenants that require the Company to maintain liquidity and net worth ratios and is secured by certain investments of the Company, which are shown as restricted cash in the accompanying consolidated balance sheets, in an amount equal to 102% of the $5,000,000 commitment, or $5,100,000. At June 28, 2003, there was no outstanding balance under the revolving line of credit. In addition, the Company was in compliance with all covenants contained in the revolving line of credit agreement as of June 28, 2003. At June 28, 2003, the interest rate on the revolving line of credit was 4.00%.

     In August 2002, the Company entered into an agreement for a $5,000,000 revolving line of credit with BSC in connection with a strategic alliance (see Note 9).

(9)      Strategic Alliance with Boston Scientific Corporation

     On August 7, 2002, the Company formed a strategic alliance with BSC. In connection with this strategic alliance, the Company sold 1,428,572 shares of the Company’s common stock at a purchase price per share of $7.00 to BSC pursuant to a stock purchase agreement. In addition, the Company granted BSC an option under an OEM product development and distribution agreement to distribute newly developed technology for monitoring patients under sedation in a range of less-invasive medical specialties. Gross cash proceeds from this sale of common stock were $10,000,004. Approximately $5,839,000 of the aggregate purchase price was recorded as deferred revenue in the accompanying consolidated balance sheet at June 28, 2003, which represents the portion of the purchase price in excess of the closing price of the Company’s common stock on August 7, 2002. The deferred revenue will be recognized ratably over the term of the OEM agreement. Approximately $154,000 was recognized as revenue in the three months ended June 28, 2003 and approximately $307,000 was recognized as revenue in the six months ended June 28, 2003. The term of the agreement continues until such time that BSC is no longer distributing the Company’s products, but in no event will extend beyond December 31, 2012.

11

ASPECT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

     As part of the strategic alliance with BSC, the Company also entered into an agreement pursuant to which BSC has agreed to provide the Company a $5,000,000 revolving line of credit, which expires in August 2007 and may be extended at the discretion of BSC. Interest on any borrowings under this revolving line of credit is at a rate equal to the LIBOR rate at which BSC, under its own revolving credit facility, is entitled to borrow funds, plus any additional amounts payable thereon by BSC under such revolving credit facility, plus eighty basis points. The Company’s revolving line of credit with BSC is secured by the Company’s inventory and certain of the Company’s accounts receivable and contains certain restrictive covenants covering the collateral. At June 28, 2003, there was no outstanding balance under this revolving line of credit, and the Company was in compliance with all covenants contained in the revolving line of credit agreement.

12

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

     This Quarterly Report on Form 10-Q contains, in addition to historical information, forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties and are not guarantees of future performance. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate” and variations of these words and similar expressions are intended to identify forward-looking statements. Our actual results could differ significantly from the results discussed in these forward-looking statements. In addition, subsequent events and developments may cause our expectations to change. While we may elect to update these forward-looking statements we specifically disclaim any obligation to do so, even if our expectations change. See the important factors in the cautionary statements below under the heading “Factors Affecting Future Operating Results” that we believe could cause our actual results to differ materially from the forward-looking statements we make.

Overview

     We develop, manufacture and market an anesthesia monitoring system that we call the BIS® system. The BIS system is based on our patented core technology, the Bispectral Index, which we refer to as the BIS index. The BIS system provides information that allows clinicians to better assess and manage a patient’s level of consciousness in the operating room and intensive care settings and administer the precise amount of anesthesia needed by each patient. Our proprietary BIS system includes our BIS monitor, or our BIS Module Kit, which allows original equipment manufacturers to incorporate the BIS index into their monitoring products, and our single-use disposable BIS Sensors. We collectively refer to our group of disposable sensors as BIS Sensors.

     Our latest generation monitor, the A-2000® BIS Monitor, was cleared for marketing by the United States Food and Drug Administration, or the FDA, in February 1998. Our latest version of the BIS system, the BIS XP system, was cleared for marketing by the FDA in June 2001. In addition to our A-2000 BIS Monitor, we offer original equipment manufacturers our BIS Module Kit for integration into equipment sold by the original equipment manufacturers.

     We follow a system of fiscal quarters as opposed to calendar quarters. Under this system, the first three quarters of each fiscal year end on the Saturday closest to the end of the calendar quarter and the last quarter of the fiscal year always ends on December 31.

     We derive our revenue primarily from sales of monitors, BIS Module Kits, and related accessories, which we collectively refer to as Equipment, and sales of BIS Sensors. In the three months ended June 28, 2003 and June 29, 2002, revenue from the sale of Equipment represented approximately 31% and 34%, respectively, of our revenue, and revenue from the sale of BIS Sensors represented approximately 69% and 66%, respectively, of our revenue. In the six months ended June 28, 2003 and June 29, 2002, revenue from the sale of Equipment represented approximately 32% and 35%, respectively, of our revenue, and revenue from the sale of BIS Sensors represented approximately 68% and 65%, respectively of our revenue.

     We believe our ability to grow our revenue is directly related to our ability to sell our Equipment to healthcare organizations and influence our customers to purchase and use our BIS Sensors. We believe the increase in our installed base of Equipment resulting from the sale of BIS monitors and the sale of original equipment manufacturers’ equipment incorporating our BIS Module Kit has been the primary reason for the growth in revenue from the sale of BIS Sensors. In order to successfully grow our business, we need to continue to focus on both selling our Equipment and improving our per monitor and per module sensor utilization rate. To achieve this growth, we continue to implement new sales and marketing programs. We expect that as we grow our business, revenue from the sale of BIS Sensors should contribute an increasing percentage of total revenue. Additionally, we believe that over time, revenue from the sale of BIS Module Kits will increase as a percentage of total Equipment revenue as healthcare organizations purchase our technology as part of the integrated solution offered by our original equipment manufacturers.

     For those healthcare organizations desiring to purchase our BIS monitors, we offer two options. Our customers have the option either to purchase BIS monitors outright or to acquire BIS monitors pursuant to a sales-type lease agreement whereby the customer contractually commits to purchase a minimum number of BIS Sensors per BIS monitor per year. Under this agreement, our customers purchase BIS Sensors and the BIS monitor for the purchase price of the BIS Sensors plus an additional charge per BIS Sensor to pay for the purchase price of the BIS monitor and related financing costs over the term of the agreement. These customers are granted an option to purchase the BIS monitors at the end of the term of the agreement, which is typically three to five years. Revenue related to BIS monitors sold pursuant to sales-type leases is recognized at the time of shipment of the BIS monitors. Sales-type leases accounted for approximately 4% and 5% of total revenue in the three months ended June 28, 2003 and June 29, 2002, respectively, and approximately 3% and 4% of total revenue in the six months ended June 28, 2003 and June 29, 2002, respectively.

13

     Under certain limited circumstances, we also offer customers the opportunity to use the BIS monitors under our Equipment Placement program, which we refer to as the EP program. Under the EP program, the customer is granted the right to use the BIS monitors for a mutually agreed upon period of time. During this period, the customer purchases BIS Sensors at a price that includes a premium above the list price of the BIS Sensors to cover the rental of the equipment, but without any minimum purchase commitments. At the end of the agreed upon period, the customer has the option of purchasing the BIS monitors, continuing to use them under the EP program or returning them to us. Beginning in 2002, we substantially reduced our focus and reliance on the EP program.

     Revenue from domestic sales in the three months ended June 28, 2003 and June 29, 2002 was approximately $8.7 million and $8.5 million, respectively, which represented approximately 81% and 85%, respectively, of our revenue for those periods. For the six months ended June 28, 2003 and June 29, 2002, revenue from domestic sales was approximately $16.6 million and $16.4 million, respectively, which represented approximately 80% and 83%, respectively, of our revenue for those periods. Revenue from international sales in the three months ended June 28, 2003 and June 29, 2002 was approximately $2.0 million and $1.5 million, respectively, which represented approximately 19% and 15%, respectively, of our revenue for those periods. Revenue from international sales in the six months ended June 28, 2003 and June 29, 2002 was approximately $4.2 million and $3.4 million, respectively, which represented approximately 20% and 17%, respectively, of our revenue for those periods.

     We have subsidiaries in The Netherlands and the United Kingdom to facilitate the sale of our products into the international market. We are continuing to develop our international sales and distribution program through a combination of distributors and marketing partners, including companies with which we have entered into original equipment manufacturer relationships. In January 1998, we entered into a distribution agreement with Nihon Kohden Corporation to distribute BIS monitors in Japan. In March 2000, Nihon Kohden received approval from the Japanese Ministry of Health, Labor and Welfare for marketing in Japan our A-1050 EEG Monitor with BIS and in May 2001, received approval for marketing in Japan our A-2000 BIS Monitor. Nihon Kohden has requested but has not yet received approval to market the BIS XP system in Japan. In January 2002, the Japanese Ministry of Health, Labor and Welfare granted reimbursement approval for use of our BIS monitors. With this approval, healthcare providers in Japan are eligible to receive partial reimbursement of 1,000 Yen each time BIS monitoring is used. In July 2002, the Japanese Ministry of Health, Labor and Welfare approved our BIS module for marketing in Japan. Sales to Nihon Kohden represented approximately 10% and 13%, respectively, of international revenue for the three and six months ended June 28, 2003 and approximately 24% and 29%, respectively of international revenue for the three and six months ended June 29, 2002.

     We believe that maintaining our gross margin and controlling the growth of our operating expenses are important factors for us to manage in order to successfully grow our business and achieve profitability. To maintain our gross margin we believe we must continue to focus on maintaining our average unit prices for both monitors and BIS Sensors, increase revenue from the sale of BIS Sensors as a percentage of total revenue, as BIS Sensors have a higher gross margin than Equipment, and continue to reduce the costs to manufacture our products.

     In addition, the transition from monitor placements to module placements has adversely impacted our gross margin on Equipment. However, we believe that this transition should, over time, improve our total gross margin as we expect module placements to be a contributing factor to increasing revenue from the sale of our BIS Sensors.

     In the fourth quarter of 2002, we reduced our headcount. We believe this headcount reduction, in combination with other cost reductions implemented in 2002 and our continuing focus on cost control in 2003, should drive us closer to our goal of achieving profitability.

     Various factors may adversely affect our quarterly operating results through the third quarter of 2003 and the year ending December 31, 2003. These factors include a potentially adverse effect on Equipment revenue and gross margin on Equipment as we continue to shift the focus of our placements from BIS monitors to BIS modules. In addition, in Japan, Nihon Kohden is awaiting approval of the BIS XP system, and we believe customers may delay purchases of our products or may choose not to purchase our products pending this approval. Finally, on November 1, 2003, our international master distribution agreement with Datex-Ohmeda expires and will be replaced by country-specific distribution agreements with Datex-Ohmeda sales subsidiaries and other distributors. A delay in signing these country-specific distribution agreements may adversely affect Equipment revenue in the international market. To date, we have entered into several new country-specific distribution agreements, and we continue to negotiate others.

14

Critical Accounting Policies

     Financial Reporting Release No. 60, which was released by the Securities and Exchange Commission, or SEC, in December 2001, proposes a rule that requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements. Note 2 of the Notes to Consolidated Financial Statements includes a summary of our significant accounting policies and methods used in the preparation of our financial statements. In preparing these financial statements, we have made estimates and judgments of certain amounts included in the financial statements. The application of these accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates. We do not believe there is a great likelihood that materially different amounts would be reported under different conditions or using different assumptions. We believe that our critical accounting policies are as follows:

   Revenue Recognition

     Our revenue is recognized in accordance with SEC Staff Accounting Bulletin, or SAB, No. 101, Revenue Recognition in Financial Statements, which provides guidance related to revenue recognition in financial statements. We recognize revenue from Equipment sales, disposable product sales and sales-type leases at the time of product shipment when collectibility is reasonably assured. Payments received prior to shipment are recorded as deferred revenue. We have entered into certain licensing and distribution agreements for which payments received in advance are also recorded as deferred revenue. Revenue under these agreements is recognized as earned in accordance with the terms of the respective agreements.

     We do not record a provision for estimated sales returns because historically we have experienced only minimal returns that were not covered by warranty reserves. To the extent returns increase in future periods, we would be required to re-evaluate our revenue recognition policy in accordance with Statement of Financial Accounting Standards, or SFAS, No. 48, Revenue Recognition When Right of Return Exists.

   Accounts Receivable

     We determine our allowance for doubtful accounts by using estimates based on our historical collections experience, current trends, historical write-offs of our receivables, credit policy and a percentage of our accounts receivable by aging category. We also review the credit quality of our customer base as well as changes in our credit policies. We continuously monitor collections and payments from our customers. While credit losses have historically been within our expectations and the provisions established, our credit loss rates in the future may not be consistent with our historical experience. To the extent we experience a deterioration in our historical collections experience or increased credit losses, bad debt expense would likely increase in future periods.

   Inventories

     We value inventory at the lower of cost or estimated market, and determine cost on a first-in, first-out basis. We regularly review inventory quantities on hand and record a provision for excess or obsolete inventory primarily based on production history and on our estimated forecast of product demand. The medical industry in which we market our products is characterized by rapid product development and technological advances that could result in obsolescence of inventory. Additionally, our estimates of future product demand may prove to be inaccurate, in which case we will need to change our estimate of the provision required for excess and obsolete inventory. If revisions are deemed necessary, we would recognize the adjustments in our costs of revenue at the time of the determination. Therefore, although we continually update our forecasts of future product demand, any significant unanticipated changes in demand or technological developments could have a significant impact on the value of our inventory and our results of operations in future periods.

15

   Investment in Sales-Type Leases

     We follow SFAS No. 13, Accounting For Leases, for our investment in sales-type leases. Under our sales-type leases, customers purchase BIS Sensors and the BIS monitor for the purchase price of the BIS Sensors plus an additional charge per BIS Sensor to pay for the purchase price of the BIS monitor and related financing costs over the term of the agreement. In accordance with SFAS No. 13, the minimum lease payment, consisting of the additional charge per BIS Sensor, less the unearned interest income, which is computed at the interest rate implicit in the lease, is recorded as net investment in sales-type leases. The cost of the BIS monitor acquired by the customer is recorded as costs of revenue in the same period.

     In addition, we periodically review and assess the net realizability of our investment in sales-type leases. This review includes determining if a customer who entered into a sales-type lease is significantly underperforming relative to the customer’s committed level of BIS Sensor purchases. If this review results in a lower estimate of the net realizable investment balance, an allowance for the unrealized amount is established in the period in which the estimate is changed and charged to revenue. Therefore, if in any period where we determine that a significant number of customers who entered into sales-type leases are underperforming in their respective commitments, it could have an impact on our results of operations.

   Warranty

     Equipment that we sell is generally covered by a warranty period of one year. We accrue a warranty reserve for estimated costs to provide warranty services. Our estimate of costs to service our warranty obligations is based on our historical experience and expectation of future conditions. While our warranty costs have historically been within our expectations and the provisions established, to the extent we experience increased warranty claim activity or increased costs associated with servicing those claims, our warranty accrual will increase, and we would experience decreased gross profit margin.

Results of Operations

     The following table presents, for the three and six month periods ended June 28, 2003 and June 29, 2002, certain information from our consolidated statements of operations expressed as a percentage of revenue. This information has been derived from our consolidated statements of operations included elsewhere in this Quarterly Report on Form 10-Q. You should not draw any conclusions about our future results from the results of operations for any period.

			Three Months Ended						Six Months Ended
			June 28, 2003			June 29, 2002			June 28, 2003			June 29, 2002
Revenue				100	%		100	%		100	%		100	%
Costs of revenue				25			30			25			33
Gross profit margin				75			70			75			67
Operating expenses:
	Research and development			18			20			18			20
	Sales and marketing			55			69			59			73
	General and administrative			20			19			21			19
		Total operating expenses		93			108			98			112
Loss from operations				(18	)		(38	)		(23	)		(45	)
Interest income, net				1			2			2			3
Net loss				(17	)%		(36	)%		(21	)%		(42	)%

16

Three and Six Months Ended June 28, 2003 Compared to Three and Six Months Ended June 29, 2002

     Revenue. Our revenue increased to approximately $10.7 million in the three months ended June 28, 2003 from approximately $10.1 million in the three months ended June 29, 2002, an increase of approximately 7%. Our revenue increased to approximately $20.8 million in the six months ended June 28, 2003 from approximately $19.7 million in the six months ended June 29, 2002, an increase of approximately 6%.

     Revenue from the sale of Equipment decreased to approximately $3.3 million in the three months ended June 28, 2003 from approximately $3.4 million in the three months ended June 29, 2002, a decrease of approximately 5%. In the six months ended June 28, 2003, Equipment revenue decreased to approximately $6.6 million from approximately $6.9 million in the six months ended June 29, 2002, a decrease of approximately 4%. The decrease in Equipment revenue in the three months ended June 28, 2003 compared to the three months ended June 29, 2002 was primarily driven by an approximate 27% decrease in monitor revenue. In the three months ended June 28, 2003 compared to the three months ended June 29, 2002, the lower monitor revenue was a result of a 44% decrease in unit volume as we shipped 280 monitors in the second quarter of 2003 compared to 503 monitors in the second quarter of 2002. The decrease in monitor unit volume for this period was related to a reduction of sales in the domestic market from 342 monitors in the second quarter of 2002 to 151 monitors in the second quarter of 2003. There was also a reduction of sales in Japan as Nihon Kohden continued to delay additional monitor purchases or decided not to purchase monitors pending Japanese Ministry of Health, Labor and Welfare approval of the XP technology. Sales of monitor units in Japan decreased from 65 monitors in the second quarter of 2002 to none in the second quarter of 2003. The decrease in monitor revenue for the three months ended June 28, 2003 compared to the three months ended June 29, 2002 was partially offset by an increase in module revenue of approximately 117%. The increase in module revenue in the second quarter of 2003 was the result of a 166% increase in the number of module kits shipped to our original equipment manufacturers, from 175 module kits in the second quarter of 2002 to 466 module kits in the second quarter of 2003.

     In the six months ended June 28, 2003 compared to the six months ended June 29, 2002, the decrease in Equipment revenue was primarily driven by an approximate 28% decrease in monitor revenue. There was a 37% decrease in unit volume as we shipped 651 monitors in the six months ended June 28, 2003 compared to 1,039 monitors in the six months ended June 29, 2002. In this same period, domestic monitor sales decreased from 571 monitors to 353 monitors, a decrease of approximately 38%. Additionally, because Nihon Kohden is awaiting approval from the Japanese Ministry of Health, Labor and Welfare of the XP technology, sales of monitor units in Japan decreased from 200 monitors in the first six months of 2002 to none in the first six months of 2003. The decrease in monitor revenue for the six months ended June 28, 2003 compared to the six months ended June 29, 2002, was partially offset by an increase in module revenue of approximately 114%. The increase in module revenue for the six months ended June 28, 2003 was the result of a 91% increase in the number of module kits shipped to our original equipment manufacturers, from 533 module kits in the first six months of 2002 to 1,018 module kits in the first six months of 2003.

     Revenue from the sale of BIS Sensors increased to approximately $7.4 million in the three months ended June 28, 2003 from approximately $6.6 million in the three months ended June 29, 2002, an increase of approximately 12%. In the six months ended June 28, 2003, revenue from the sale of BIS Sensors increased to approximately $14.2 million from approximately $12.9 million in the six months ended June 29, 2002, an increase of approximately 11%. The increase in revenue from the sale of BIS Sensors in the three and six months ended June 28, 2003 compared to the three and six months ended June 29, 2002 was primarily attributable to an increase of approximately 10% and 7%, respectively, in the number of BIS Sensors sold as a result of growth in the installed base of monitors and modules. The average selling price of BIS Sensors increased approximately 2% and 3%, respectively, in the three and six months ended June 28, 2003 compared to the three and six months ended June 29, 2002. Our installed base of monitors and modules increased approximately 20% at June 28, 2003 compared to June 29, 2002, to more than 17,800 units.

     Our gross profit margin was approximately 75% of revenue in both the three and six months ended June 28, 2003 compared to a gross profit margin of approximately 70% and 67% of revenue in the three and six months ended June 29, 2002, respectively. The increase in gross profit margin for the three and six months ended June 28, 2003 compared to the three and six months ended June 29, 2002 was the result of five factors. First, we experienced increased sales of our BIS Sensors as a percentage of total revenue during both the three and six month periods, and in the same periods there was an increase in the average unit price for BIS Sensors. BIS Sensors have a higher gross margin than Equipment. Second, there was a higher average unit price on monitors. Third, we had improved gross margin on ancillary items primarily as a result of an increase in the average unit price for BIS XP upgrade kits of approximately 20% and 175% for the three and six month periods, respectively. Fourth, we had a reduction in depreciation expense related to monitors used in the EP program as the existing pool of monitors becomes fully depreciated and we substantially reduce our focus and reliance on the EP program. Finally, we recognized approximately $154,000 and $307,000 of deferred revenue in the three and six months ended June 28, 2003 related to the strategic alliance with Boston Scientific Corporation without any corresponding costs of revenue, increasing the gross profit margin by approximately 2% in both the three and six month periods.

17

     Research and Development. Research and development expenses decreased to approximately $1.9 million in the three months ended June 28, 2003 from approximately $2.0 million in the three months ended June 29, 2002, a decrease of approximately 8%. Research and development expenses decreased to approximately $3.7 million in the six months ended June 28, 2003 from approximately $4.0 million in the six months ended June 29, 2002, a decrease of approximately 5%. The decrease in research and development expenses for the three months ended June 28, 2003 compared to the three months ended June 29, 2002, was primarily attributable to a decrease in personnel and related payroll and other expenses of approximately $198,000 and a decrease in clinical studies expenses of approximately $92,000. These decreases were offset by increases in consulting expenses of approximately $96,000 and product development expenses of approximately $74,000.

     The decrease in research and development expenses for the six months ended June 28, 2003 compared to the six months ended June 29, 2002, was primarily attributable to a decrease in personnel and related payroll and other expenses of approximately $363,000, offset by increases in consulting expenses of approximately $160,000, product development expenses of approximately $77,000 and patent related expenses of approximately $46,000. We expect research and development expenses to increase slightly in the third quarter of 2003 compared to the second quarter of 2003 as we continue to invest in clinical studies and expand applications for our technology, including our initiatives into neuroscience.

     Sales and Marketing. Sales and marketing expenses decreased to approximately $5.9 million in the three months ended June 28, 2003 from approximately $7.0 million in the three months ended June 29, 2002, a decrease of approximately 15%. Sales and marketing expenses decreased to approximately $12.2 million in the six months ended June 28, 2003 from approximately $14.3 million in the six months ended June 29, 2002, a decrease of approximately 14%. The decrease in sales and marketing expenses in the three months ended June 28, 2003 compared to the three months ended June 29, 2002, was attributable to decreases in personnel and related payroll and other expenses of approximately $312,000, operating expenses associated with our international subsidiaries of approximately $464,000, approximately $70,000 in clinical education initiatives and approximately $50,000 in other marketing expenses. These decreases were partially offset by increases in market research and consulting expenses of approximately $106,000. The decrease of approximately $464,000 in operating expenses associated with our international subsidiaries was driven by a decrease in personnel related payroll and other expenses of approximately $330,000 which related to the reduction in force announced in November 2002.

     The decrease in sales and marketing expenses for the six months ended June 28, 2003 compared to the six months ended June 29, 2002 was primarily attributable to decreases in personnel and related payroll and other expenses of approximately $311,000, operating expenses associated with our international subsidiaries of approximately $787,000, approximately $399,000 in expenses related to advertising, public relations, tradeshows and the internet and approximately $116,000 in clinical education initiative expenses. These decreases were partially offset by increases in market research and consulting expenses of approximately $100,000. The decrease of approximately $787,000 in operating expenses associated with our international subsidiaries was driven by a decrease of approximately $545,000 in personnel related payroll and other expenses. We expect sales and marketing expenses in the third quarter of 2003 to increase compared to the second quarter of 2003 as we continue to complement our existing sales and marketing programs with additional programs, including a program with an emphasis on patient safety.

     General and Administrative. General and administrative expenses increased to approximately $2.2 million in the three months ended June 28, 2003 from approximately $1.9 million in the three months ended June 29, 2002, an increase of approximately 13%. General and administrative expenses increased to approximately $4.3 million in the six months ended June 28, 2003 from approximately $3.8 million in the six months ended June 29, 2002, an increase of approximately 13%. The increase in general and administrative expenses for the three months ended June 28, 2003 was primarily attributable to increases in personnel related payroll and other expenses of approximately $236,000. These increases were offset by a decrease of approximately $50,000 in our provision for doubtful accounts. In the six months ended June 28, 2003, the increase in general and administrative expenses was related to an increase in personnel and related payroll and other expenses of approximately $468,000 and an increase of approximately $80,000 in insurance expense which is primarily a result of an increase in the directors and officers insurance premium. These increases were offset by a decrease of approximately $100,000 in our provision for doubtful accounts due to improvements in our historical collection experience. We expect general and administrative expenses in the third quarter of 2003 to remain comparable to the second quarter of 2003.

18

     Interest Income, Net. Net interest income decreased to approximately $184,000 in the three months ended June 28, 2003 from approximately $228,000 in the three months ended June 29, 2002, a decrease of approximately 19%. Net interest income decreased to approximately $379,000 in the six months ended June 28, 2003 from approximately $503,000 in the six months ended June 29, 2002, a decrease of approximately 25%. Interest income decreased to approximately $236,000 in the three months ended June 28, 2003 from approximately $283,000 in the three months ended June 29, 2002, a decrease of approximately 17%. Interest income decreased to approximately $486,000 in the six months ended June 28, 2003 from approximately $628,000 in the six months ended June 29, 2002, a decrease of approximately 23%. The decrease in interest income was primarily attributable to lower cash and investment balances resulting from continued operating losses and our other uses of cash, and lower interest rates on our investments as a result of general interest rate declines.

     Interest expense decreased to approximately $52,000 in the three months ended June 28, 2003 from approximately $55,000 in the three months ended June 29, 2002, a decrease of approximately 5%. Interest expense decreased to approximately $108,000 in the six months ended June 28, 2003 from approximately $125,000 in the six months ended June 29, 2002, a decrease of approximately 14%. The decrease in interest expense in the three and six months ended June 28, 2003 was a result of lower average outstanding debt obligations because we did not draw down on our line of credit for the three and six months ended June 28, 2003. We expect net interest income to decrease slightly in the third quarter of 2003 as compared to the second quarter of 2003 as a result of continuing low interest rates and a lower cash and investments balance.

     Net Loss. As a result of the factors discussed above, for the three and six months ended June 28, 2003, we had a net loss of approximately $1.8 million and $4.3 million, respectively, as compared to a net loss of approximately $3.7 million and $8.4 million for the three and six months ended June 29, 2002.

Liquidity and Capital Resources

     Our liquidity requirements have historically consisted of research and development expenses, sales and marketing expenses, capital expenditures, working capital and general corporate expenses. From our inception through January 2000, we financed our operations primarily from the sale of our convertible preferred stock. Through June 28, 2003, we raised approximately $77.6 million from private equity financings and have received approximately $3.4 million in equipment financing and approximately $5.1 million of financing related to our investments in sales-type leases. We also received approximately $2.8 million of financing under a term loan in December 1999. The outstanding principal on the equipment and term loans was paid in May 2001. In February 2000, we closed our initial public offering of an aggregate of 4,025,000 shares of common stock and received net proceeds of approximately $54.6 million. In May 2001, we entered into an agreement with Fleet National Bank for a $5.0 million revolving line of credit which expires in May 2004. The revolving line of credit agreement contains restrictive covenants that require us to maintain liquidity and net worth ratios and is secured by certain of our investments which are shown as restricted cash on our consolidated balance sheets. We are required to maintain restricted cash and securities with a net equity value equal to 102% of the $5.0 million commitment.

     In August 2002, we entered into a strategic alliance with Boston Scientific Corporation whereby we sold 1,428,572 shares of our common stock at a purchase price per share of $7.00 to Boston Scientific Corporation pursuant to a stock purchase agreement. Gross cash proceeds from this sale of common stock were $10,000,004.

     We also entered into an agreement with Boston Scientific Corporation for a revolving line of credit under which we are entitled to borrow up to $5.0 million under the revolving line of credit which expires in August 2007 and may be extended at the discretion of Boston Scientific Corporation. Interest on any borrowings under this revolving line of credit is at a rate equal to the LIBOR rate at which Boston Scientific Corporation, under its own revolving credit facility, is entitled to borrow funds plus any additional amounts payable thereon by Boston Scientific Corporation under such revolving credit facility, plus eighty basis points. Our revolving line of credit with Boston Scientific Corporation is secured by our inventory and certain of our accounts receivable and contains certain restrictive covenants covering the collateral. At June 28, 2003, there was no outstanding balance under this revolving line of credit.

     We expect to meet our short-term liquidity needs through the use of cash and short-term investments on hand at June 28, 2003.

     We believe that the financial resources available to us, including our current working capital and available revolving lines of credit will be sufficient to finance our planned operations and capital expenditures through the end of 2004. However, our future liquidity and capital requirements will depend upon numerous factors, including the resources required to further develop our marketing and sales organization domestically and internationally, to finance our research and development programs, to implement new marketing programs, to finance our sales-type lease program and to meet market demand for our products.

19

     Working capital at June 28, 2003 was approximately $33.2 million compared to approximately $36.7 million at December 31, 2002. The decrease in working capital from December 31, 2002 to June 28, 2003 was primarily attributable to our continued net loss of approximately $4.3 million.

     We used approximately $4.7 million of cash for operations in the six months ended June 28, 2003 as compared to approximately $7.3 million in the six months ended June 29, 2002. Cash used for operations in the six months ended June 28, 2003 was primarily driven by operating losses, an increase in accounts receivable of approximately $955,000, an increase in other assets of approximately $428,000 and a decrease in deferred revenue of approximately $474,000, offset by a decrease in inventory of approximately $595,000.

     We received approximately $6.2 million of cash from investing activities in the six months ended June 28, 2003 as compared to approximately $13.1 million in the six months ended June 29, 2002. The cash received from investing activities in the six months ended June 28, 2003 was primarily the result of the sales and maturities of our investments in marketable securities. We received approximately $6.3 million, net, of proceeds from sales and maturities of marketable securities and invested approximately $260,000 primarily for improvements to our information systems in the six months ended June 28, 2003. In the six months ended June 29, 2002, we received approximately $13.7 million, net, of proceeds from sales and maturities of marketable securities and invested approximately $606,000 primarily in information systems and machinery and equipment.

     We received approximately $48,000 of cash from financing activities in the six months ended June 28, 2003 primarily as a result of proceeds from the sale of our investment in sales-type leases of approximately $266,000, payments received on notes receivable from employees and directors of approximately $144,000 and the issuance of shares of our common stock upon the exercise of stock options and for purchases under our employee stock purchase plan of approximately $143,000, partially offset by payments of principal on debt related to our investment in sales-type leases of approximately $504,000. In the six months ended June 29, 2002, we received approximately $148,000 of cash from financing activities as a result of proceeds from the sale of our investment in sales-type leases of approximately $313,000 and the issuance of shares of our common stock upon the exercise of stock options and for purchases under our employee stock purchase plan of approximately $305,000, offset by principal payments on debt related to our investment in sales-type leases of approximately $496,000.

     In May 2001, we entered into an agreement with Fleet National Bank for a revolving line of credit, which provides for borrowing of up to $5.0 million. The revolving line of credit expires in May 2004 and, subject to annual review by the bank, may be extended at the discretion of Fleet National Bank. Interest on any borrowings under the revolving line of credit is, at our election, either the prime rate or at LIBOR plus 2.25%. At June 28, 2003, the interest rate on the line of credit was 4.00%. The revolving line of credit agreement contains restrictive covenants that require us to maintain liquidity and net worth ratios and is secured by certain of our investments which are shown as restricted cash on our consolidated balance sheet. We are required to maintain restricted cash and securities with a net equity value equal to 102% of the $5.0 million commitment. Up to $1.5 million of the $5.0 million revolving line of credit is available for standby letters of credit. There was no outstanding balance under the line of credit at June 28, 2003. At June 28, 2003, we had standby letters of credit outstanding in the amount of $190,137.

     We guarantee approximately $224,000 of operating lease obligations of our subsidiaries for the lease of office space and automobiles.

     In July 1999, we entered into an agreement under which we can sell a portion of our existing and future investments in sales-type leases to Americorp Financial, Inc. Through June 28, 2003, we sold approximately $5.1 million of our investments in sales-type leases. In accordance with SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities — A replacement of FASB Statement No. 125, the proceeds from these sales are classified as debt. Payments on the outstanding principal under this debt match the timing of the payments due on the underlying investments in sales-type leases. At June 28, 2003, approximately $1.7 million is recorded as debt on our consolidated balance sheet.

     We had capital expenditures of approximately $260,000 for the six months ended June 28, 2003, primarily for improvements to our information systems. At June 28, 2003, we did not have any commitments for capital expenditures. We anticipate that the level of capital expenditures in the third quarter of 2003 will be slightly higher than the total capital expenditures for the first half of 2003.

20

     We have summarized below our contractual cash obligations as of June 28, 2003:

	Payments Due By Period
			Less Than		One to Three		Three to Five		More Than
Contractual Obligations	Total		One Year		Years		Years		Five Years
Operating lease obligations	$	3,810,808	$	1,229,025	$	2,084,185	$	497,598	$	—
Debt related to the sale of investment in sales-type leases	$	1,663,954	$	825,356	$	718,473	$	120,125	$	—
Total	$	5,474,762	$	2,054,381	$	2,802,658	$	617,723	$	—

Income Taxes

     We have net operating loss and research and development tax credit carryforwards for federal income tax purposes that began expiring in the year 2002 and will continue to expire through the year 2022 if not utilized.

     The net operating loss and research and development tax credit carryforwards are subject to review by the Internal Revenue Service. Ownership changes, as defined under Section 382 in the Internal Revenue Code, may limit the amount of these tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.

Effects of Inflation

     We believe that inflation and changing prices over the past year have not had a significant impact on our revenue or on our results of operations.

Conversion to Euro

     Twelve of the 15 members of the European Union have adopted the Euro as their legal currency. Our current information systems allow us to process Euro-denominated transactions. We are also assessing the business implications of the conversion to the Euro, including long-term competitive implications and the effect of market risk with respect to financial instruments. The majority of our international sales are denominated in U.S. dollars. We do not believe the Euro has had a significant effect on our business, financial condition or results of operations. However, the expenses and capital spending of our international subsidiaries are transacted in the respective country’s local currency. As a result, changes in foreign currency exchange rates or weak economic conditions in foreign markets could affect our financial condition or results of operations.

Recent Accounting Pronouncements

     In November 2002, the FASB issued Financial Interpretation No. 45, or FIN 45, Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others. FIN 45 requires a guarantor to disclose (a) the nature of the guarantee, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments under the guarantee; (c) the carrying amount of the liability, if any, for the guarantor’s obligations under the guarantee; and (d) the nature and extent of any recourse provisions or available collateral that would enable the guarantor to recover the amounts paid under the guarantee. FIN 45 also clarifies that a guarantor is required to recognize, at the inception of a guarantee, a liability at fair value for the obligations it has undertaken in issuing the guarantee, including its ongoing obligation to stand ready to perform over the term of the guarantee in the event that the specified triggering events or conditions occur. The initial recognition and initial measurement provisions of FIN 45 are applicable on a prospective basis to guarantees issued or modified after December 31, 2002. FIN 45 also addresses the disclosure requirements regarding product warranties. Instead of disclosing the maximum potential amount of future payments under the product warranty guarantee, a guarantor is required to disclose its accounting policy and methodology used in determining its liability for product warranties, as well as, a tabular reconciliation of the changes in the guarantor’s product warranty liability for the reporting period. We adopted FIN 45 as of January 1, 2003. The adoption of FIN 45 did not have a material effect on our results of operations, cash flows or financial position.

21

     In January 2003, the FASB issued FIN 46, Consolidation of Variable Interest Entities. FIN 46 requires that if an entity has a controlling financial interest in a variable interest entity, the assets, liabilities and results of activities of the variable interest entity should be included in the consolidated financial statements of the entity. FIN 46 is effective immediately for all new variable interest entities created or acquired after January 31, 2003. For variable interest entities created or acquired prior to February 1, 2003, the provisions of FIN 46 must be applied for the first interim or annual period beginning after June 15, 2003. We adopted FIN 46 as of January 1, 2003. The adoption of FIN 46 did not have a material effect on our results of operations, cash flows or financial position.

FACTORS AFFECTING FUTURE OPERATING RESULTS

     This Quarterly Report on Form 10-Q includes forward-looking statements, including information relating to our ability to achieve profitability, information with respect to market acceptance of our BIS system, continued growth in sales of our BIS monitors, BIS Module Kits and BIS Sensors, our dependence on the BIS system, our ability to remain competitive and achieve future growth, information with respect to other plans and strategies for our business and factors that may influence our revenue for the fiscal quarter ending September 27, 2003 and for the year ending December 31, 2003. The following important factors represent current challenges to us that create risk and uncertainty. Failure to adequately overcome any of the following challenges could have a material adverse effect on our results of operations, business or financial condition.

We will not be profitable if hospitals and anesthesia providers do not buy and use our BIS system in sufficient quantities.

     Our customers may determine that the cost of the BIS system exceeds cost savings in drugs, personnel and post-anesthesia care recovery resulting from use of the BIS system. In addition, hospitals and anesthesia providers may not accept the BIS system as an accurate means of assessing a patient’s level of consciousness during surgery or in the intensive care unit. If extensive or frequent malfunctions occur, these providers may also conclude that the BIS system is unreliable. If hospitals and anesthesia providers do not accept the BIS system as cost-effective, accurate and reliable, they will not buy and use the BIS system in sufficient quantities to enable us to be profitable.

     The success of our business also depends in a large part on continued use of the BIS system by our customers and, accordingly, sales by us of BIS Sensors. We expect that over time sales of BIS Sensors will increase as a percentage of our revenue as compared to sales of Equipment as we build our installed base of monitors and modules. If use of our BIS system, and accordingly, sales of our BIS Sensors, do not increase, it could adversely affect our revenue.

We depend on our BIS system for substantially all of our revenue, and if the BIS system does not gain widespread market acceptance, then our revenue will not grow.

     We began selling our current BIS system in early 1998 and introduced the latest version, the BIS XP system, at the end of the third fiscal quarter of 2001. In 2002, we introduced commercially the BIS Extend Sensor for patients who are monitored over an extended period of time, such as in intensive care unit settings. To date, we have not achieved widespread market acceptance of the BIS system for use in the operating room or in the intensive care unit. Because we depend on our BIS system for substantially all of our revenue and we have no other significant products, if we fail to achieve widespread market acceptance for the BIS system, we will not be able to sustain or grow our product revenue.

Various market factors may adversely affect our quarterly operating results through the third fiscal quarter of 2003 and for the year ending December 31, 2003.

     Various factors may adversely affect our quarterly operating results through the third fiscal quarter of 2003 and for the year ending December 31, 2003. First, we continue to shift the focus of our placements from BIS monitors to BIS modules which may lead to a reduction in Equipment revenue and gross margin on Equipment. Second, in Japan, Nihon Kohden is awaiting approval of the BIS XP system from the Japanese Ministry of Health, Labor and Welfare which may cause possible delays in purchasing decisions by customers in Japan, or these potential customers may choose not to purchase our products. Third, on November 1, 2003, our international master distribution agreement with Datex-Ohmeda expires and will be replaced by country-specific distribution agreements with Datex-Ohmeda sales subsidiaries and other distributors. A delay in signing these country-specific distribution agreements may adversely affect Equipment revenue in the international market. The continuation of difficult worldwide economic conditions, reductions in hospital purchasing programs, and the cost of transitioning our installed base to the new BIS XP system may also adversely impact our revenue and operating results through the third fiscal quarter of 2003 and for the year ending December 31, 2003.

22

Fluctuations in our quarterly operating results could cause our stock price to decrease.

     Our operating results have fluctuated significantly from quarter to quarter in the past and are likely to vary in the future. These fluctuations are due to several factors relating to the sale of our products, including:

• the timing and volume of customer orders for our BIS system,

• the introduction of the BIS XP system,

• implementation of, and our subsequent reduction on the focus of, our EP program,

• use of and demand for our BIS Sensors,

• transition of sales focus from BIS monitors to BIS module kits,

• customer cancellations,

• introduction of competitive products,

• regulatory approvals,

• changes in management,

• turnover in our direct sales force,

• effectiveness of new marketing and sales programs,

• reductions in orders by our distributors and original equipment manufacturers, and

• the timing and amount of our expenses.

     Because of these fluctuations, it is likely that in some future quarter or quarters our operating results could again fall below the expectations of securities analysts or investors. If our quarterly operating results are below expectations in the future, the market price of our common stock would also likely decrease. In addition, because we do not have a significant backlog of customer orders for our BIS system, revenue in any quarter depends on orders received in that quarter. Our quarterly results may also be adversely affected because some customers may have inadequate financial resources to purchase our products or may fail to pay for our products after receiving them. In particular, hospitals are increasingly experiencing financial constraints, consolidations and reorganizations as a result of cost containment measures and declining third-party reimbursement for services, which may result in decreased product orders or an increase in bad debts in any quarter.

If the estimates we make, and the assumptions on which we rely in preparing our financial statements prove inaccurate, our actual results may vary from those reflected in our projections and accruals.

     Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us, such as those made in connection with our restructurings, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. There can be no assurance, however, that our estimates, or the assumptions underlying them, will be correct.

If approval of our BIS XP system is not obtained in Japan, our revenue and operating results could be adversely affected.

     In Japan, Nihon Kohden is awaiting approval of the BIS XP system from the Japanese Ministry of Health, Labor and Welfare. Until approval is obtained, customers in Japan may delay their purchasing decisions with respect to our products or may decide not to purchase our products at all. As a result, if approval for this product is not obtained in Japan in the near future, or at all, it could limit the growth of our international revenue.

23

We may need additional financing for our future capital needs and may not be able to raise additional funds on terms acceptable to us, or at all.

     We believe that the financial resources available to us, including our current working capital and available revolving lines of credit, will be sufficient to finance our planned operations and capital expenditures through the end of 2004. If we are unable to increase our revenue and achieve positive cash flow, we will need to raise additional funds. We may also need additional financing if:

• we need additional cash to fund research and development costs of products currently under development,

• we decide to expand faster than currently planned,

• we develop new or enhanced services or products ahead of schedule,

• we decide to undertake new sales and/or marketing initiatives,

• we are required to defend or enforce our intellectual property rights,

• sales of our products do not meet our expectations in the United States or internationally,

• we need to respond to competitive pressures, or

• we decide to acquire complementary products, businesses or technologies.

     We can provide no assurance that we will be able to raise additional funds on terms acceptable to us, if at all. If future financing is not available or is not available on acceptable terms, we may not be able to fund our future needs which would significantly limit our ability to implement our business plan. In addition, we may have to issue securities that may have rights, preferences and privileges senior to our common stock.

Cases of surgical awareness during monitoring with the BIS system could limit market acceptance of BIS systems and could expose us to product liability claims.

     Clinicians have reported to us cases of possible surgical awareness during surgical procedures monitored with the BIS system. In most of the cases that were reported to us, when BIS index values were recorded at the time of awareness, high BIS index values were noted, indicating that the BIS index correctly identified the increased risk of awareness in these patients. However, in a small number of these reported cases, surgical awareness may not have been detected by monitoring with the BIS system. It is possible that additional cases of surgical awareness during surgical procedures monitored with the BIS system have not been reported to us, and we have not systematically solicited reports of surgical awareness. Anesthesia providers and hospitals may elect not to purchase and use BIS systems if there is adverse publicity resulting from the report of cases of surgical awareness that were not detected during procedures monitored with the BIS system. If anesthesia providers and hospitals do not purchase and use the BIS system, then we may not sustain or grow our product revenue. Although we do not claim that patient monitoring with the BIS system will reduce the incidence of surgical awareness, we may be subject to product liability claims for cases of surgical awareness during surgical procedures monitored with the BIS system. These claims could require us to spend significant time and money in litigation or to pay significant damages.

     We are currently evaluating the data that was collected in our three multi-center, multinational studies to assess the incidence of awareness during BIS monitoring. Abstracts summarizing the findings of these studies were accepted by the American Society of Anesthesiologists, or ASA, for presentation at the annual meeting in October 2003. If the results of these studies do not conclusively demonstrate that patient monitoring with the BIS system will reduce the incidence of surgical awareness or if the patient safety benefits of BIS monitoring are not persuasive enough to lead to wider adoption of our BIS technology, our business could be adversely affected.

24

We may not be able to compete with new products or alternative techniques developed by others, which could impair our ability to remain competitive and achieve future growth.

     The medical industry in which we market our products is characterized by rapid product development and technological advances. Our competitors have introduced commercially three anesthesia monitoring products approved by the United States Food and Drug Administration, or FDA. If we do not compete effectively with these monitoring products, our revenue will be adversely affected. Our current or planned products are at risk of obsolescence from:

• other new monitoring products, based on new or improved technologies,

• new products or technologies used on patients or in the operating room during surgery in lieu of monitoring devices,

• electrical or mechanical interference from new or existing products or technologies,

• alternative techniques for evaluating the effects of anesthesia,

• significant changes in the methods of delivering anesthesia, and

• the development of new anesthetic agents.

     We may not be able to improve our products or develop new products or technologies quickly enough to maintain a competitive position in our markets and continue to grow our business.

If we do not successfully develop and introduce enhanced or new products we could lose revenue opportunities and customers.

     As the market for our BIS system matures, we need to develop and introduce new products for anesthesia monitoring or other applications. In 2002, we introduced commercially the BIS Extend Sensor for patients who are typically monitored for an extended period of time, such as in intensive care unit settings. We do not know whether the use of the BIS system and the BIS Extend Sensor for use in the intensive care unit will achieve market acceptance. In addition, we have begun to research the use of BIS monitoring to diagnose and track neurological diseases, and face at least the following two related risks:

• we may not successfully adapt the BIS system to function properly for procedural sedation, when used with anesthetics we have not tested or with patient populations we have not studied, such as infants, and

• our technology is complex, and we may not be able to develop it further for applications outside anesthesia monitoring, such as the diagnosis and tracking of neurological diseases.

     If we do not successfully adapt the BIS system for new products and applications both within and outside the field of anesthesia monitoring, or if such products and applications are developed but not successfully commercialized, then we could lose revenue opportunities and customers.

25

If we do not develop and implement a successful sales and marketing strategy, we will not expand our business.

     In the past, we have experienced high turnover in our direct sales force. It is possible that turnover may occur in the future. If new sales representatives do not acquire the technological skills to sell our products in a timely and successful manner or we continue to experience high turnover in our direct sales force, we may not be able to sustain and grow our product revenue. On an ongoing basis, we develop and introduce new sales and marketing programs. If we do not implement these new sales and marketing programs in a timely and successful manner, we may not be able to achieve the level of market awareness and sales required to expand our business. We have only limited sales and marketing experience both in the United States and internationally and may not be successful in developing and implementing our strategy. We need to:

• provide or assure that distributors and original equipment manufacturers provide the technical and educational support customers need to use the BIS system successfully,

• promote frequent use of the BIS system so that sales of our disposable BIS Sensors increase,

• establish and implement successful marketing and sales programs that encourage our customers to purchase our products or the products that are made by original equipment manufacturers incorporating our technology,

• manage geographically dispersed operations, and

• modify our products and marketing and sales programs for foreign markets.

In order to reach the level of sales we need to achieve profitability, we need to further develop our direct and indirect sales channels.

     In order to increase our sales, we need to continue to strengthen our relationships with our domestic and international distributors and continue to add international distributors. We need to also continue to strengthen our relationships with our original equipment manufacturers and other sales channels and increase sales through these channels. On an ongoing basis we develop and implement new sales and marketing programs and clinical education programs to promote the use of the BIS system by our customers. If we do not further develop our direct and indirect sales channels and successfully implement the new sales and marketing programs and clinical education programs that encourage our customers to purchase and use our products, we will not reach the level of sales necessary to achieve profitability.

Our third-party distribution and original equipment manufacturer relationships could negatively affect our profitability, cause sales of our products to decline and be difficult to terminate if we are dissatisfied.

     Sales through distributors could be less profitable than direct sales. Sales of our products through multiple channels could also confuse customers and cause the sale of our products to decline. We do not control our original equipment manufacturers and distribution partners. Our partners could sell competing products, may not incorporate our technology into their products in a timely manner and may devote insufficient sales efforts to our products. Our partners are generally not required to purchase minimum quantities. As a result, even if we are dissatisfied with the performance of our partners, we may be unable to terminate our agreements with these partners or enter into alternative arrangements.

We may not be able to generate enough additional revenue from our international expansion to offset the costs associated with establishing and maintaining foreign operations.

     A component of our growth strategy is to expand our presence in foreign markets. We conduct international business primarily in Europe and Japan and we are attempting to increase the number of countries in which we do business. It is costly to establish international facilities and operations and to promote the BIS system in international markets. We have encountered barriers to the sale of our BIS system outside the United States, including less acceptance by anesthesia providers for use of disposable products, such as BIS Sensors, delays in regulatory approvals outside of the United States, particularly in Japan, and difficulties selling through indirect sales channels. In addition, we have little experience in marketing and distributing products in these markets. Revenue from international activities may not offset the expense of establishing and maintaining these foreign operations.

26

We may not be able to meet the unique operational, legal and financial challenges that we will encounter in our international operations, which may limit the growth of our business.

     We are increasingly subject to a number of challenges which specifically relate to our international business activities. These challenges include:

• failure of local laws to provide the same degree of protection against infringement of our intellectual property,

• protectionist laws and business practices that favor local competitors, which could slow our growth in international markets,

• difficulties in terminating or modifying distributor arrangements because of restrictions in markets outside the United States,

• less acceptance by foreign anesthesia providers of the use of disposable products similar to the BIS Sensors,

• delays in regulatory approval of our products,

• currency conversion issues arising from sales denominated in currencies other than the United States dollar,

• foreign currency exchange rate fluctuations,

• longer sales cycles to sell products like the BIS system to hospitals and outpatient surgical centers, which could slow our revenue growth from international sales, and

• longer accounts receivable payment cycles and difficulties in collecting accounts receivable.

     If we are unable to meet and overcome these challenges, our international operations may not be successful which would limit the growth of our business.

We may experience customer dissatisfaction and our reputation could suffer if we fail to manufacture enough products to meet our customers’ demands.

     We rely on third-party manufacturers to assemble and manufacture the components of our BIS monitors, BIS Module Kits and a portion of our BIS Sensors. We manufacture substantially all BIS Sensors in our own manufacturing facility. We have only one manufacturing facility. If we fail to produce enough products at our own manufacturing facility or at a third-party manufacturing facility or experience a termination or modification of any manufacturing arrangement with a third party, we may be unable to deliver products to our customers on a timely basis. Our failure to deliver products on a timely basis could lead to customer dissatisfaction and damage our reputation.

Our reliance on sole-source suppliers could adversely affect our ability to meet our customers’ demands for our products in a timely manner or within budget.

     Some of the components that are necessary for the assembly of our BIS system, including some of the components used in our BIS Sensors, are currently provided to us by sole-source suppliers or a limited group of suppliers. We purchase components through purchase orders rather than long-term supply agreements and generally do not maintain large volumes of inventory. We have experienced shortages and delays in obtaining some of the components of our BIS systems in the past, and we may experience similar shortages or delays in the future. The disruption or termination of the supply of components could cause a significant increase in the costs of these components, which could affect our profitability. A disruption or termination in the supply of components could also result in our inability to meet demand for our products, which could lead to customer dissatisfaction and damage our reputation. Furthermore, if we are required to change the manufacturer of a key component of the BIS system, we may be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could delay our ability to manufacture BIS systems in a timely manner or within budget.

27

We may be required to bring litigation to enforce our intellectual property rights, which may result in substantial expense and may divert our attention from the implementation of our business strategy.

     We believe that the success of our business depends, in part, on obtaining patent protection for our products, defending our patents once obtained and preserving our trade secrets. We rely on a combination of contractual provisions, confidentiality procedures and patent, trademark and trade secret laws to protect the proprietary aspects of our technology. These legal measures afford only limited protection and competitors may gain access to our intellectual property and proprietary information. Litigation may be necessary to enforce our intellectual property rights, to protect our trade secrets and to determine the validity and scope of our proprietary rights. Any litigation could result in substantial expense and diversion of our attention from the growth of the business and may not be adequate to protect our intellectual property rights.

We may be sued by third parties which claim that our products infringe on their intellectual property rights, particularly because there is substantial uncertainty about the validity and breadth of medical device patents.

     We may be exposed to litigation by third parties based on claims that our products infringe the intellectual property rights of others. This risk is exacerbated by the fact that the validity and breadth of claims covered in medical technology patents involve complex legal and factual questions for which important legal principles are unresolved. Any litigation or claims against us, whether or not valid, could result in substantial costs, could place a significant strain on our financial resources and could harm our reputation. In addition, intellectual property litigation or claims could force us to do one or more of the following:

• cease selling, incorporating or using any of our products that incorporate the challenged intellectual property, which would adversely affect our revenue,

• obtain a license from the holder of the infringed intellectual property right, which license may not be available on reasonable terms, if at all, and

• redesign our products, which would be costly and time-consuming.

We could be exposed to significant product liability claims which could divert management attention and adversely affect our cash balances, our ability to obtain and maintain insurance coverage at satisfactory rates or in adequate amounts and our reputation.

     The manufacture and sale of our products expose us to product liability claims and product recalls, including those which may arise from misuse or malfunction of, or design flaws in, our products or use of our products with components or systems not manufactured or sold by us. Product liability claims or product recalls, regardless of their ultimate outcome, could require us to spend significant time and money in litigation or to pay significant damages. We currently maintain product liability insurance; however, it may not cover the costs of any product liability claims made against us. Furthermore, we may not be able to obtain insurance in the future at satisfactory rates or in adequate amounts. In addition, publicity pertaining to the misuse or malfunction of, or design flaws in, our products could impair our ability to successfully market and sell our products.

Several class action lawsuits have been filed against the underwriters of our initial public offering which may result in negative publicity and potential litigation against us that would be costly to defend and the outcome of which is uncertain and may harm our business.

     The underwriters of our initial public offering are named as defendants in several class action complaints which have been filed allegedly on behalf of certain persons who purchased shares of our common stock between January 28, 2000 and December 6, 2000. These complaints allege violations of the Securities Act of 1933 and the Securities Exchange Act of 1934. Primarily they allege that there was undisclosed compensation received by our underwriters in connection with our initial public offering. While we and our officers and directors have not been named as defendants in these suits, based on comparable lawsuits filed against other companies, there can be no assurance that we and our officers and directors will not be named in similar complaints in the future. In addition, the underwriters may assert that we are liable for some or all of any liability that they are found to have to the plaintiffs, pursuant to the indemnification provisions of an underwriting agreement we entered into as part of the initial public offering, or otherwise.

28

     We can provide no assurance as to the outcome of these complaints or any potential suit against us or our officers and directors. Any conclusion of these matters in a manner adverse to us could have a material adverse affect on our financial position and results of operations. In addition, the costs to us of defending any litigation or other proceeding, even if resolved in our favor, could be substantial. Such litigation could also substantially divert the attention of our management and our resources in general. Uncertainties resulting from the initiation and continuation of any litigation or other proceedings and the negative publicity associated with this litigation could harm our ability to compete in the marketplace.

Boston Scientific Corporation may be able to impact corporate actions requiring stockholder approval because it owns a significant amount of our common stock, and, if our strategic alliance with Boston Scientific Corporation is not successful, our operating results will be adversely affected.

     As of August 4, 2003, Boston Scientific Corporation owned approximately 18% of our outstanding common stock. We have an agreement with Boston Scientific Corporation, pursuant to which Boston Scientific Corporation has agreed not to acquire any shares of our common stock in excess of 25% of the outstanding shares of common stock prior to December 31, 2004 without our prior approval. If Boston Scientific Corporation increases its ownership of our outstanding common stock, it may impact corporate actions requiring stockholder approval. In addition, on August 7, 2002, we formed a strategic alliance with Boston Scientific Corporation. In connection with this strategic alliance, we entered into an agreement pursuant to which we granted Boston Scientific Corporation an option to distribute newly developed technology for monitoring patients under sedation in a range of less-invasive medical specialties. If such products are not successfully developed, marketed and sold under the agreement in a manner consistent with our expectations, the growth of our business and our operating results will be adversely affected. Even if we successfully develop new sedation management technology for less-invasive medical procedures, Aspect and Boston Scientific Corporation may not successfully market and sell this new technology.

We may not reserve amounts adequate to cover product obsolescence, claims and returns, which could result in unanticipated expenses and fluctuations in operating results.

     Depending on factors such as the timing of our introduction of new products which utilize our BIS technology, as well as warranty claims and product returns, we may need to reserve amounts in excess of those currently reserved for product obsolescence, excess inventory, warranty claims and product returns. These reserves may not be adequate to cover all costs associated with these items. If these reserves are inadequate, we would be required to incur unanticipated expenses which could result in unexpected fluctuations in quarterly operating results.

We may not be able to compete effectively, which could result in price reductions and decreased demand for our products.

     We are facing increased competition in the domestic level of consciousness monitoring market as a result of three competitors’ monitoring systems which have been approved by the FDA. These products are marketed by well-established medical products companies with significant resources. We may not be able to compete effectively with these and other potential competitors. We may also face substantial competition from companies which may develop sensor products that compete with our proprietary BIS Sensors for use with our BIS monitors or with third-party monitoring systems or anesthesia delivery systems that incorporate the BIS index. We also expect to face competition from companies currently marketing conventional electroencephalogram, or EEG, monitors using standard and novel signal-processing techniques. Other companies may develop anesthesia-monitoring systems that perform better than the BIS system and/or sell for less. In addition, one or more of our competitors may develop products that are substantially equivalent to our FDA-approved products, in which case they may be able to use our products as predicate devices to more quickly obtain FDA approval of their competing products. Medical device companies developing these and other competitive products may have greater financial, technical, marketing and other resources than we do. Competition in the sale of anesthesia-monitoring systems could result in price reductions, fewer orders, reduced gross margins and loss of market share.

29

Our ability to market and sell our products and generate revenue depends upon receipt of domestic and foreign regulatory approval of our products and manufacturing operations.

     Before we can market new products in the United States, we must obtain clearance from the FDA. If the FDA concludes that any of our products do not meet the requirements to obtain clearance of a premarket notification under Section 510(k) of the Food, Drug and Cosmetic Act, then we would be required to file a premarket approval application. The approval process for a premarket approval application is lengthy, expensive and typically requires extensive preclinical and clinical trial data. We may not obtain clearance of a 510(k) notification or approval of a premarket approval application with respect to any of our products on a timely basis, if at all. If we fail to obtain timely clearance or approval for our products, we will not be able to market and sell our products, which will limit our ability to generate revenue. We may also be required to obtain clearance of a 510(k) notification from the FDA before we can market certain previously marketed products which we modify after they have been cleared. We have made certain enhancements to our currently marketed products which we have determined do not necessitate the filing of a new 510(k) notification. However, if the FDA does not agree with our determination, it will require us to file a new 510(k) notification for the modification and we may be prohibited from marketing the modified device until we obtain FDA clearance. We have filed a 510(k) application with the FDA to revise product indications for use to reflect results from our awareness trials. If this application is not approved by the FDA, it could have an adverse affect on our operations.

     The FDA also requires us to adhere to current Good Manufacturing Practices regulations, which include production design controls, testing, quality control, storage and documentation procedures. The FDA may at any time inspect our facilities to determine whether adequate compliance has been achieved. Compliance with current Good Manufacturing Practices regulations for medical devices is difficult and costly. In addition, we may not continue to be compliant as a result of future changes in, or interpretations of, regulations by the FDA or other regulatory agencies. If we do not achieve continued compliance, the FDA may withdraw marketing clearance or require product recall. When any change or modification is made to a device or its intended use, the manufacturer may be required to reassess compliance with current Good Manufacturing Practices regulations, which may cause interruptions or delays in the marketing and sale of our products.

     Sales of our products outside the United States are subject to foreign regulatory requirements that vary from country to country. The time required to obtain approvals from foreign countries may be longer than that required for FDA approval, and requirements for foreign licensing may differ from FDA requirements.

     The federal, state and foreign laws and regulations regarding the manufacture and sale of our products are subject to future changes, as are administrative interpretations of regulatory agencies. If we fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, including product seizures, recalls, withdrawal of clearances or approvals and civil and criminal penalties.

If we do not retain our senior management and other key employees, we may not be able to successfully implement our business strategy.

     Our president and chief executive officer, Nassib Chamoun, joined us at our inception in 1987. Our chairman, J. Breckenridge Eagle, began serving as a director in 1988. Many other members of our management and key employees have extensive experience with us and other companies in the medical device industry. Our success is substantially dependent on the ability, experience and performance of these members of our senior management and other key employees. Because of their ability and experience, if we lose one or more of the members of our senior management or other key employees, our ability to successfully implement our business strategy could be seriously harmed.

If we do not attract and retain skilled personnel, we will not be able to expand our business.

     Our products are based on complex signal-processing technology. Accordingly, we require skilled personnel to develop, manufacture, sell and support our products. Our future success will depend largely on our ability to continue to hire, train, retain and motivate additional skilled personnel, particularly sales representatives who are responsible for customer education and training and post-installation customer support. Consequently, if we are not able to attract and retain skilled personnel, we will not be able to expand our business.

30

Failure of users of the BIS system to obtain adequate reimbursement from third-party payors could limit market acceptance of the BIS system, which could prevent us from achieving profitability.

     Anesthesia providers are generally not reimbursed separately for patient monitoring activities utilizing the BIS system. For hospitals and outpatient surgical centers, when reimbursement is based on charges or costs, patient monitoring with the BIS system may reduce reimbursements for surgical procedures, because charges or costs may decline as a result of monitoring with the BIS system. Failure by hospitals and other users of the BIS system to obtain adequate reimbursement from third-party payors, or any reduction in the reimbursement by third-party payors to hospitals and other users as a result of using the BIS system could limit market acceptance of the BIS system, which could prevent us from achieving profitability.

Item 3.     Qualitative and Quantitative Disclosures About Market Risk.

     We are exposed to financial market risks, including changes in foreign currency exchange rates and interest rates. Most of our revenue, expenses and capital spending are transacted in U.S. dollars. However, the expenses and capital spending of our international subsidiaries are transacted in the respective country’s local currency. As a result, changes in foreign currency exchange rates or weak economic conditions in foreign markets could affect our financial results. We do not use derivative instruments to hedge our foreign exchange risk. Our exposure to market risk for changes in interest rates relates primarily to our cash and cash equivalent balances, marketable securities, investment in sales-type leases and line of credit agreements. The majority of our investments are in short-term instruments and subject to fluctuations in U.S. interest rates. Due to the nature of our short-term investments, we believe that there is no material market risk.

Item 4.     Controls and Procedures.

(a)	Evaluation of Disclosure Controls and Procedures
	Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act) as of June 28, 2003. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of June 28, 2003, our disclosure controls and procedures were (1) designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our chief executive officer and chief financial officer by others within those entities, particularly during the period in which this report was being prepared and (2) effective, in that they provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.
(b)	Changes in Internal Controls
	No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act) occurred during the fiscal quarter ended June 28, 2003 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

31

PART II — OTHER INFORMATION

Item 1.        Legal Proceedings.

We are not a party to any material threatened or pending legal proceedings.

Item 2.        Changes in Securities and Use of Proceeds.

     On February 2, 2000, we sold 3,500,000 shares of our common stock, at an initial public offering price of $15.00 per share, pursuant to a Registration Statement on Form S-1 (Registration No. 333-86295), which was declared effective by the Securities and Exchange Commission on January 27, 2000. On February 4, 2000, the underwriters exercised in full their over-allotment option to purchase an additional 525,000 shares of our common stock at $15.00 per share. The managing underwriters of our initial public offering were Morgan Stanley & Co. Incorporated, Deutsche Bank Securities Inc. and U.S. Bancorp Piper Jaffray Inc.

     The aggregate gross proceeds raised in the offering were approximately $60.4 million. Our total expenses in connection with the offering were approximately $5.7 million, of which $4.2 million was for underwriting discounts and commissions and, based on our reasonable estimate, approximately $1.5 million was for other expenses. Our net proceeds from the offering were approximately $54.6 million. From January 27, 2000 through June 28, 2003, we used approximately $9.0 million of the net proceeds for the acquisition of machinery and equipment, leasehold improvements, furniture and fixtures, demonstration and evaluation equipment and new information systems. In addition, from January 27, 2000 through June 28, 2003, we used approximately $38.8 million of the net proceeds for general corporate purposes, including working capital, product development, increasing our sales and marketing capabilities and expanding our international operations. As of June 28, 2003, we had approximately $6.8 million of proceeds remaining from the offering, and pending use of the proceeds, we have invested these funds in short-term, interest-bearing, investment-grade securities.

Item 3.        Defaults Upon Senior Securities.

None.

Item 4.        Submission of Matters to a Vote of Security Holders.

     On May 20, 2003, we held our 2003 annual meeting of stockholders. At the meeting, Nassib G. Chamoun, Lester John Lloyd and James J. Mahoney were elected as Class III Directors of Aspect, to serve until our 2006 annual meeting of stockholders and until their successors are duly elected and qualified. In addition, our stockholders ratified the selection of Ernst & Young LLP by our board of directors as our independent auditors for the fiscal year ending December 31, 2003.

     Mr. Chamoun received 16,388,635 shares of common stock voting in favor of his election, and 11,473 shares of common stock were withheld. Mr. Lloyd received 16,373,289 shares of common stock voting in favor of his election, and 26,819 shares of common stock were withheld. Mr. Mahoney received 16,350,920 shares of common stock voting in favor of his election, and 49,188 shares of common stock were withheld. 16,375,029 shares of common stock voted in favor of ratifying the board of directors’ selection of Ernst & Young LLP as our independent auditors and 1,238 shares of common stock voted against ratifying the board of directors’ selection of Ernst & Young LLP as our independent auditors.

     The terms of office of the following directors continued after our 2003 annual meeting of stockholders: Richard J. Meelia, Donald R. Stanski, Boudewijn L.P.M. Bollen, J. Breckenridge Eagle and Edwin M. Kania.

Item 5.        Other Information.

None.

32

Item 6.        Exhibits and Reports on Form 8-K.

     (a) Exhibits

The exhibits listed in the Exhibit Index immediately preceding the exhibits are filed as part of this Quarterly Report on Form 10-Q.

     (b) Reports on Form 8-K

On April 16, 2003 we furnished a Current Report on Form 8-K to the Securities and Exchange Commission announcing our financial results for the fiscal quarter ended March 29, 2003. The date of this Current Report on Form 8-K is April 16, 2003.

33

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ASPECT MEDICAL SYSTEMS, INC.
Date: August 11, 2003	By:	/s/ J. Neal Armstrong
		J. Neal Armstrong
		Vice President and Chief Financial Officer
		(Principal Financial and Accounting Officer)

34

EXHIBIT INDEX

EXHIBIT
NUMBER	EXHIBIT
31.1	Certification by Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2	Certification by Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1	Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.